Techniques in Cellular and Molecular Neurobiology

"

International Master's Degree in Neuroscience

Lesson 8



Gabriele Baj gbaj@units.it







NIH Public Access

Author Manuscript

Cell. Author manuscript; available in PMC 2011 November 12.

Published in final edited form as:

Cell. 2010 November 12; 143(4): 527-539. doi:10.1016/j.cell.2010.10.016.

A model for neural development and treatment of Rett Syndrome using human induced pluripotent stem cells

Maria C. N. Marchetto^{1,†}, Cassiano Carromeu^{2,†}, Allan Acab², Diana Yu¹, Gene Yeo³, Yangling Mu¹, Gong Chen⁴, Fred H. Gage¹, and Alysson R. Muotri^{2,*}

¹ The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA


Background




Autism spectrum disorders (ASD) are complex neurodevelopmental diseases in which different combinations of genetic mutations may contribute to the phenotype.

Using Rett syndrome (RTT) as an ASD genetic model, we developed a culture system using induced pluripotent stem cells (iPSCs) from RTT patients' fibroblasts.

RTT patients' iPSCs are able to undergo X-inactivation and generate functional neurons. Neurons derived from RTT-iPSCs had fewer synapses, reduced spine density, smaller soma size, altered calcium signaling and electrophysiological defects when compared to controls. Our data uncovered early alterations in developing human RTT neurons. Finally, we used RTT neurons to test the effects of drugs in rescuing synaptic defects.








Generation of iPSCs. (A), Schematic representation of the MeCP2 gene structure and mutations used in this study







Representative images of teratoma sections.

NOTE: iPSCs are validated using animal models




































Е































Induced pluripotent stem cell models of the genomic imprinting disorders Angelman and Prader-Willi syndromes

Stormy J. Chamberlain^{a,b,2}, Pin-Fang Chen^b, Khong Y. Ng^b, Fany Bourgois-Rocha^{b,1}, Fouad Lemtiri-Chlieh^c, Eric S. Levine^c, and Marc Lalande^{a,b,2}

^aUniversity of Connecticut Stem Cell Institute and Departments of ^bGenetics and Developmental Biology and ^aNeuroscience, University of Connecticut Health Center, Farmington, CT 06030

Edited by C. Thomas Caskey, University of Texas-Houston Health Science Center, Houston, TX, and approved August 27, 2010 (received for review April 3, 2010)

Annalosa andreas (AC) and Dorder (ACII) andreas (DIAIC) and Describe


Background



Angelman syndrome (AS) is a neurodevelopmental disorders of genomic imprinting. AS results from loss of function of the ubiquitin protein ligase E3A (UBE3A) gene.


Biological question


Can we generate a model of AS in vitro?







Immunocytochemistry for pluripotency markers on representative iPSC lines shows expression of NANOG (d–f), SSEA4 (g–i), TRA1-60 (j–l), and TRA1-81 (m–p).













Functional neurons can be generated from AS iPSCs.

(A) Phase-contrast image of 10-wk-old in vitro differentiated neurons generated from AS iPSCs.

Α







Paternal UBE3A is repressed in AS iPSC-derived neurons.

(A) qRT-PCR analysis of UBE3A expression in AS and normal iPSCs and iPSC-derived neurons.

Gene expression is normalized to GAPDH and is presented as the fold change relative to UBE3A expression levels in normal iPSCs.

B) Western blot analysis of normal and AS iPSCs (I) and 10-wk-old iPSC-derived neurons (N).



EBioMedicine 50 (2019) 274-289



Contents lists available at ScienceDirect

EBioMedicine





Research paper

Human iPSC-derived astrocytes from ALS patients with mutated C9ORF72 show increased oxidative stress and neurotoxicity



Anastasya Birger^{a,b}, Israel Ben-Dor^a, Miri Ottolenghi^a, Tikva Turetsky^a, Yaniv Gil^a, Sahar Sweetat^b, Liat Perez^b, Vitali Belzer^b, Natania Casden^b, Debora Steiner^a, Michal Izrael^c, Eithan Galun^d, Eva Feldman^e, Oded Behar^{b,*}, Benjamin Reubinoff^{a,*}

Background



- Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects motorneurons(MNs).
- It was shown that human astrocytes with mutations in genes associated with ALS, like C9orf72(C9) or SOD1, reduce survival of MNs.
- Astrocyte toxicity may be related to their dysfunction or the release of neurotoxic factors.


Biological question



The role of astrocytes in ALS caused by C9orf72 mutation and the mechanism of the possible induced toxicity

Methods

- They used human induced pluripotent stem cell-derived astrocytes from ALS patients carrying
 C9orf72 mutations and non-affected donors.
- We utilized these cells to investigate astrocytic induced neuronal toxicity, changes in astrocyte
 transcription profile as well as changes in secretome profiles






Generation of functional astrocytes from C9 mutated and control iPSClines.


(a) Schematic presentation of the protocol for induction of astrocyte differentiation.






NOTE: Comparison with mouse model already studied





NOTE: Comparison with mouse model already studied



Merge

100 um


HB9-GFP

UNIVERSITÀ DEGLI STUDI DI TRIESTE

Results


Generation of functional motorneurons.







Toxicity of media conditioned by C9-mutated astrocytes to human iPSC-derived motorneurons.













c Enriched pathways based on down-regulated genes








C9 mutated astrocytes acquire senescence phenotype at higher rates than non-mutated astrocytes.





C9 mutated astrocytes show higher percentage of ROS-positive cells and their secretome can induce higher ROS levels in MNs.







